Optimized labeling of NOTA-conjugated octreotide with F-18

Peter Laverman · Christopher A. D’Souza · Annemarie Eek · William J. McBride · Robert M. Sharkey · Wim J. G. Oyen · David M. Goldenberg · Otto C. Boerman

Received: 23 August 2011 / Accepted: 5 October 2011 / Published online: 19 October 2011 © The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract We recently reported a facile method based on the chelation of [18F]aluminum fluoride (Al18F) by NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid). Here, we present a further optimization of the 18F labeling of NOTA-octreotide (IMP466). Octreotide was conjugated with the NOTA chelate and was labeled with 18F in a two-step, one-pot method. The labeling procedure was optimized with regard to the labeling buffer, ionic strength, peptide concentration, and temperature. Radiochemical yield, specific activity, in vitro stability, and receptor affinity were determined. Biodistribution of 18F-IMP466 was studied in AR42J tumor-bearing mice. In addition, microPET/CT images were acquired. IMP466 was labeled with Al18F in a single step with 97% yield in the presence of 80% (v/v) acetonitrile or ethanol. The labeled product was purified by HPLC to remove unlabeled peptide and unbound Al18F. The radiolabeling, including purification, was performed for 45 min. Specific activities of 48,000 GBq/mmol could be obtained. 18F-IMP466 showed a high tumor uptake and excellent tumor-to-blood ratios at 2 h post-injection. In addition, the low bone uptake indicated that the Al18F-NOTA complex was stable in vivo. PET/CT scans revealed excellent tumor delineation and specific accumulation in the tumor. Uptake in receptor-negative organs was low. NOTA-octreotide could be labeled with 18F in quantitative yields using a rapid two-step, one-pot, method. The compound was stable in vivo and showed rapid accretion in SSTR2-receptor-expressing AR42J tumors in nude mice. This method can be used to label other NOTA-conjugated compounds such as RGD peptides, GRPR-binding peptides, and Affibody molecules with 18F.

Keywords Octreotide · Radiofluorination · NOTA · Peptide · PET · Aluminum fluoride

Introduction

Radiolabeled receptor-binding peptides have emerged as an important class of radiopharmaceuticals that have changed radionuclide imaging. Peptides have been labeled with 111In and 99mTc for SPECT imaging and with positron emitters such as 68Ga, 64Cu, 86Y, and 18F for PET imaging. 18F is the most widely used radionuclide in PET and has excellent characteristics for peptide-based imaging since the half-life (110 min) matches the pharmacokinetics of most peptides. In addition, the low positron energy of 635 keV results in short ranges in tissue, which results in excellent preclinical imaging resolution (<2 mm). Various methods to label peptides with 18F have been investigated. Usually, a nucleophilic substitution reaction is used to produce an 18F-labeled synthon, which is then reacted with a (functionalyzed) peptide. One of the first generally applicable methods—and still most widely used—is based on conjugation of the synthon, N-succinimidyl-4-[18F]fluorobenzoate, to a primary amino group of the peptide [1].
method requires a time-consuming and laborious multistep synthesis. Specific activities obtained with this method ranged from 57,900 to 147,000 GBq/mmol [2]. Searching for a faster method, Wester et al. developed an improved $^{18}$F-labeling method. This procedure is based on the reaction of $[^{18}$F]fluorobenzaldehyde with an aminooxy-derivatized peptide, resulting in a stable oxime bond [3]. The specific activities of the radiolabeled peptides were not mentioned. Others showed that $[^{18}$F]fluorobenzaldehyde could also be reacted with hydrazino nicotinamide-conjugated peptides [4, 5]. The specific activity which could be achieved with an $^{18}$F-labeled leukotriene B4 antagonist was 1,200 GBq/mmol [5]. To take advantage of the widespread availability of $[^{18}$F]FDG, two groups explored $[^{18}$F]FDG for labeling of aminooxy-derivatized peptides [6, 7]. Although it was shown that these functionalized peptides could be labeled with $[^{18}$F]FDG, these methods require the use of carrier-free $[^{18}$F]FDG, necessitating HPLC purification of $[^{18}$F]FDG before conjugation with the peptide. Specific activities were not reported. Additionally, methods based on the broadly used Huisgen cycloaddition of alkynes and azides were explored for the radiofluorination of peptides [8–12]. Specific activities varied considerably from 4,800–12,300 GBq/mmoll [8] to 100,000–200,000 GBq/mmoll [12]. In search for a kit-based radiofluorination method, silicon-based building blocks were used to fluorinate bone-targeting peptides. To improve the stability of the $^{18}$F-labeled peptides, they required to be functionalized with two tertiary butyl groups. This resulted in a lipophilic $^{18}$F-peptide and loss of tumor targeting [13, 14]. The maximal specific activity was 62,000 GBq/mmol. All of these methods require azeotropic drying of $^{18}$F in the presence of a cryptand, such as Kryptofix (K$_{222}$).

We recently reported that NOTA-conjugated peptides could be labeled directly with $^{18}$F using aluminum to bind $^{18}$F [15–17]. With this two-step one-pot fluorination method, the peptide could be stably labeled with a 50% radiochemical yield at a high-specific activity within 45 min. Here, we present an optimization of the aluminum fluoride NOTA chelator labeling.

Materials and methods

Peptide synthesis

The octreotide peptide analog (IMP466), NOTA-D-Phe-cyclo[Cys-Phe-D-Trp-Lys-Thr-Cys]-Throl (MH$^{+}$ 1305), was synthesized using standard Fmoc-based solid phase peptide synthesis. After the peptide was cleaved from the resin, the peptide was cyclized by overnight incubation with DMSO. The Throl resin and the protected amino acids were purchased from CreoSalus Inc. (Louisville, KY). The bis-$r$-butyl NOTA ligand was provided by Immunomedics, Inc. All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO) or Fisher Scientific (Pittsburgh, PA). All buffers used for radiolabeling were metal-free.

Radiolabeling

$^{18}$F-labeling

A Chromafix PS-HCO$_3$ cartridge (ABX, Radeberg, Germany) with 4–6 GBq $^{18}$F (BV Cyclotron VU, Amsterdam, The Netherlands) was washed with 3 mL of metal-free water. $^{18}$F was eluted from the cartridge with 100 μL 0.9% NaCl. To the eluted Na$^{18}$F, 2 mM AlCl$_3$ in 0.1 M sodium acetate buffer, pH 4, was added (8.5 μL AlCl$_3$ per GBq $^{18}$F). Then, 10–50 μL IMP466 (10 mg/mL) was added in 5.0 M sodium acetate (pH 4.1) and also 6 μg/mL gentisic acid. The reaction mixture was incubated at 100°C for 15 min unless stated otherwise. The radiolabeled peptide was purified on an RP-HPLC as described below. The $^{18}$F-IMP466-containing fractions were collected and diluted twofold with H$_2$O and purified on an Oasis HLB cartridge (1 cc, 30 mg, Waters, Milford, MA) to remove acetonitrile and trifluoroacetic acid (TFA). In brief, the fraction was applied on the cartridge and the cartridge was washed with 3 mL H$_2$O. The radiolabeled peptide was then eluted with 2×200 μL 50% ethanol. Upon injection in mice, the peptide was diluted with 0.9% NaCl.

Effect of buffer

The effect of the buffer on the labeling efficiency of IMP466 with $^{18}$F$^{-}$ was investigated ($n$=3 for each buffer). IMP466 was dissolved at 10 mg/mL (7.7 mM) in sodium citrate buffer, sodium acetate buffer, 2-(N-morpholino)ethanesulfonic acid (MES), or 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer. The molarity of all buffers was 1 M and the pH was 4.1. To 153 nmol (200 μg) of IMP466, 100 μL Al$^{18}$F (pH 4.1) was added and incubated at 100°C for 15 min. Radio-labeling yield and specific activity were determined with RP-HPLC as described below.

Effect of hydrophilic organic solvent

The effect of the ionic strength on the labeling efficiency of IMP466 with $^{18}$F$^{-}$ was investigated ($n$=3 for each buffer). To IMP466 [100 μg (77 nmol) in 25 μL in sodium acetate buffer], 180 μL (unless stated otherwise) of acetonitrile, ethanol, dimethylformamide (DMF), or tetrahydrofuran (THF) was added [final concentration 80% (v/v)]. Finally, 20 μL Al$^{18}$F (pH 4) was added and the mixture was
incubated at 100°C for 15 min. Radiolabeling yield and specific activity were determined with RP-HPLC as described below.

**Effect of temperature**

The effect of the temperature on the labeling efficiency of IMP466 with ¹⁸F was investigated (n=3 for each temperature). To IMP466 [77 nmol (100 μg) in 25 μL in sodium acetate buffer] 180 μL of acetonitrile and 20 μL “Al¹⁸F” (pH 4) were added. The mixtures were incubated at 40°C, 50°C, 60°C, or 100°C for 15 min. Radiolabeling yield and specific activity were determined with RP-HPLC as described below.

**HPLC analysis**

The radiolabeled preparations were analyzed by RP-HPLC on an Agilent 1200 system (Agilent Technologies, Palo Alto, CA, USA). Samples containing organic solvents were diluted 50-fold before injection on HPLC. A C18 column (Onyx monolithic, 4.6×100 mm, Phenomenex, Torrance, CA, USA) was used at a flow rate of 2 mL/min with the following buffer system: buffer A, 0.1% v/v TFA in water; buffer B, 0.1% v/v TFA in acetonitrile; and gradient, 0–5 min 97% buffer A, 5–35 min 80% buffer A to 75% buffer A. The radioactivity of the eluate was monitored using an in-line NaI radiodetector (Raytest GmbH, Straubenhardt, Germany). Elution profiles were analyzed using Gina-star software (version 2.18, Raytest GmbH, Straubenhardt, Germany). Specific activity was determined by HPLC using calibration curves based on the UV signal.

**Stability**

Ten microliters of the ¹⁸F-labeled IMP466 was incubated in 500 μL of freshly collected human serum and incubated for 4 h at 37°C. An equal volume of acetonitrile was added and the mixture was vortexed followed by centrifugation at 1,000×g for 5 min to pellet the precipitated serum proteins. The supernatant was analyzed on RP-HPLC as described above.

The in vivo stability of ¹⁸F-IMP466 was examined by injecting 18.5 MBq of ¹⁸F-IMP466 in a BALB/c nude mouse. After 10 min incubation at RT in binding buffer, ¹⁸F-IMP466 or ¹¹⁵In-DTPA-octreotide was added at a final concentration ranging from 0.1 to 1,000 nM, together with a trace amount (10,000 cpm) of ¹¹¹In-DTPA-octreotide (OctreoScan®) was radiolabeled according to the manufacturer’s protocol.

AR42J cells were grown to confluency in 12-well plates and washed twice with binding buffer (DMEM with 0.5% bovine serum albumin). After 10 min incubation at RT in binding buffer, ¹⁸F-IMP466 or ¹¹⁵In-DTPA-octreotide was added at a final concentration ranging from 0.1 to 1,000 nM, together with a trace amount (10,000 cpm) of ¹¹¹In-DTPA-octreotide (radiochemical purity >95%). After incubation at RT for 3 h, the cells were washed twice with ice-cold PBS. Cells were scrapped and cell-associated radioactivity was determined. Under these conditions, some internalization may occur. We therefore describe the results of this competitive binding assay as “apparent IC₅₀” values rather than IC₅₀. The apparent IC₅₀ was defined as the peptide concentration at which 50% of binding without competitor was reached. Apparent IC₅₀ values were calculated using GraphPad Prism software (version 4.00 for Windows, GraphPad Software, San Diego, CA, USA).

**Biodistribution studies**

Male nude BALB/c mice (6–8 weeks old) were injected subcutaneously with 0.2 mL AR42J cell suspension of 1×10⁷ cells/mL. When tumors were 5–8 mm in diameter, 370 kBq ¹⁸F-labeled IMP466 (0.2 nmol) was administered intravenously (n=5). Separate groups of mice (n=5) were co-injected with a 1,000-fold molar excess of unlabeled IMP466. One group of three mice was injected with unchelated (Al¹⁸F)²⁺. All mice were killed by CO₂/O₂ asphyxiation 2 h post-injection (p.i.). Tissues of interest
were dissected, weighed, and counted in a gamma counter. The percentage of the injected dose per gram tissue was calculated. The animal experiments were approved by the local animal welfare committee and performed according to national regulations.

**PET/CT imaging**

Mice with s.c. AR42J tumors were injected intravenously with 10 MBq $^{18}$F-IMP466 (0.7 nmol) per mouse. One and 2 h after the injection of peptide, mice were scanned on an animal PET/CT scanner (Inveon®, Siemens Preclinical Solutions, Knoxville, TN) with an intrinsic spatial resolution of 1.5 mm [18]. The animals were placed in a supine position in the scanner. PET emission scans were acquired over 15 min, followed by a CT scan for anatomical reference (spatial resolution 113 $\mu$m, 80 kV, 500 $\mu$A). Scans were reconstructed using Inveon Acquisition Workplace software version 1.5 (Siemens Preclinical Solutions, Knoxville, TN), using an ordered set expectation maximization-3D/maximum a posteriori (OSEM3D/MAP) algorithm with the following parameters: matrix 256×256×159, pixel size 0.43×0.43×0.8 mm$^3$, and a beta-value of 1.5.

**Statistical analysis**

All mean values are given ± standard deviation. Statistical analysis was performed using a Welch’s corrected unpaired Student’s $t$ test or one-way analysis of variance using GraphPad InStat software (version 3.06, GraphPad Software). The level of significance was set at $P<0.05$.

**Results**

**RP-HPLC analysis**

As shown previously, HPLC analysis of the reaction mixture (Fig. 1) demonstrated the presence of unbound (Al$^{18}$F)$^{2+}$ ($R_t$ 0.8 min) and two radioactive peptide peaks with retention times of 17.4 and 19.8 min [16]. Recent date revealed that these two peaks may be due to hindered rotation of the complex with F-18 in an axial position [19]. In addition, a UV peak of IMP466 is present ($R_t$ 21.4 min). The radiolabeled $^{18}$F-IMP66 could be obtained carrier-free after HPLC and HLB purification. This was confirmed by HPLC analysis: both the unbound (Al$^{18}$F)$^{2+}$ and the unlabeled IMP466 UV peaks disappeared (Fig. 1).

**Effect of buffer**

As reported previously, when the labeling procedure was performed using sodium acetate, MES, or HEPES, radio-labeling yields were 49±2%, 46±2%, and 48±3%, respectively ($n=3$ for each buffer) [16]. In sodium citrate, no radiolabeling was observed. Specific activities of the purified peptides were in the same range for all buffers used. In sodium acetate buffer, the specific activity was 32,000±17,000 GBq/mmol, whereas in MES and HEPES buffers, specific activities were 29,000±14,000 and 31,000±23,000 GBq/mmol, respectively.

**Effect of hydrophilic organic solvent**

To investigate whether the labeling efficiency could be improved by lowering the ionic strength, the labeling reaction with (Al$^{18}$F)$^{2+}$ was performed in the presence of increasing concentrations of acetonitrile: 25%, 50%, 67%, or 80% (v/v) acetonitrile. Labeling efficiency at 25% was 40±5% and increased to 60±15% and 87±9% at 50% and 67%, respectively. Highest labeling efficiency was obtained at 80% (v/v) acetonitrile, 97±2%.

In addition, the effect of other organic solvents was investigated. Labeling efficiency in the presence of ethanol and DMF was 97±2% and 97±3%, respectively. Radio-labeling efficiency in THF was 92±7%. When the labeling
reaction was performed in the absence of organic solvent, the labeling efficiency was 46±7%.

Effect of temperature

The effect of the incubation temperature was studied using the optimal labeling condition described above, i.e., in the presence of 80% (v/v) acetonitrile. Labeling efficiency improved with increasing temperatures: at 40°C, the labeling efficiency was 30±21%, and at 50°C, the yield was 61±14%. At a temperature of 60°C, the labeling efficiency was 83±19%.

IC₅₀ determination

We previously demonstrated that the IC₅₀ was not affected by the radiofluorination [16]. Briefly, the apparent IC₅₀ of Al¹⁸F-labeled IMP466 was 3.6±0.6 nM. The apparent IC₅₀ of the reference peptide, ¹¹⁵In-DTPA-octreotide (Octreoscan®), was 6.3±0.9 nM. The affinity profiles are shown in Fig. 2.

Stability

In line with previous results [16], ¹⁸F-labeled IMP466 did not release (Al¹⁸F)²⁺ after incubation in human serum at 37°C for 4 h, indicating excellent stability of the Al¹⁸F-NOTA-octreotide.

Biodistribution studies

The biodistribution of ¹⁸F-IMP466 in BALB/c nude mice with s.c. AR42J tumors at 2 h p.i. is summarized in Fig. 3 (data adapted from [16]). Unchelated (Al¹⁸F)²⁺ was included as a control. Tumor uptake of ¹⁸F-IMP466 was 28.3±5.7% ID/g at 2 h p.i. Tumor uptake in the presence of an excess of unlabelled IMP466 was significantly decreased (8.6±0.7% ID/g, P<0.002), indicating that tumor uptake was receptor-mediated. Blood levels were low (0.10±0.07% ID/g, 2 h p.i.), which resulted in a tumor-to-blood ratio of 300±90. Uptake in normal tissues, except in the kidneys, was low. Receptor-mediated uptake was observed in SST₂ receptor-expressing tissues, such as adrenal glands, pancreas, and stomach. Bone uptake of ¹⁸F-IMP466 was very low as compared to uptake after injection of non-chelated (Al¹⁸F)²⁺ (0.33±0.07 vs. 36.9±5.0% ID/g at 2 h p.i., respectively; P<0.001), indicating good in vivo stability of the ¹⁸F-IMP466.

Discussion

Radiolabeling of peptides with fluorine-18 generally involves laborious and time-consuming procedures and first requires the synthesis of an ¹⁸F-labeled synthon. In our initial studies, we have shown that a NOTA-conjugated pretargeting peptide (IMP449) could be labeled with Al¹⁸F to yield a product with a good biodistribution profile [17]. These studies were performed with ¹⁸F⁻ that was eluted from a QMA cartridge with KHCO₃ and required careful neutralization with acetic acid in an effort to control the pH. Subsequently, we found that the varying radiochemical yields arising during the neutralization could be avoided if the ¹⁸F⁻ was eluted with 0.9% saline [15].
In the present study, we used a NOTA which was covalently linked to the peptide, using one of the carboxylic groups. Recent findings indicated that this chelator performed equally well as the isothiocyanato-benzyl derivative of NOTA [16, 17]. We found that the labeling of NOTA-octreotide failed in the presence of sodium citrate buffer. This might be due to the high affinity of citric acid for Al (III), as described by Rajan et al. [20]. Recently, we obtained considerable improvements in radiochemical yields when the labeling was performed in the presence of an organic hydrophilic solvent [19]. Herein we describe the optimization of the $^{18}$F-labeling of NOTA-octreotide (IMP466).

The labeling yield improved considerably when performing the reaction at a lower ionic strength using either acetonitrile, ethanol, or DMF. For subsequent experiments, we used acetonitrile which could easily be evaporated after the labeling reaction. Lowering the amount of acetonitrile resulted in lower labeling yields. Obviously, for future clinical studies, the use of ethanol is preferred over acetonitrile.

The peptide concentration plays a crucial role in the Al$^{18}$F-NOTA-labeling reaction. A labeling yield of 52% was obtained at a peptide concentration of 204 μM in the presence of 67% acetonitrile. In a previous study [16], a peptide concentration of 1,815 μM was required to obtain a 50% labeling efficiency. This optimal concentration is approximately tenfold lower as reported for other peptide fluorination methods [1, 3, 5].

The radiolabeled peptide could be obtained carrier-free after preparative HPLC separation on a monolithic C-18 column. Purification on a cartridge was not feasible due to the small difference in organic solvent concentration required to separate the labeled from the unlabeled peptide on HPLC.

We demonstrated that the affinity of $^{18}$F-NOTA-octreotide was at least as good as that of $^{111}$In-DTPA-octreotide and was comparable with values reported in literature for DOTA-octreotate and DOTA-TOC [21].

The biodistribution of the $^{18}$F-NOTA-octreotide was studied in AR42J tumor-bearing mice. $^{18}$F-IMP466 showed a high tumor uptake at 2 h p.i., with lower uptake in all other organs. The in vivo studies also showed the excellent stability of the Al$^{18}$F–NOTA complex, since no significant bone uptake could be measured, and the intact product was isolated in the urine.

The current method can be performed in one pot, is fast (45 min), yields carrier-free fluorinated peptide in nearly quantitative yield, and does not affect the pharmacokinetics of octreotide. In most $^{18}$F-labeling strategies for peptides...
and proteins, a fluorinated synthon such as succinimidyl-[\(^{18}\text{F}\)]fluorobenzoate [1], 4-[\(^{18}\text{F}\)]fluorobenzaldehyde [3], and 2-[\(^{18}\text{F}\)]fluoropropionic acid 4-nitrophenyl ester [22] needs to be synthesized first. In general, these fluorination methods are based on a nucleophilic substitution which requires laborious azeotropic drying of the \([^{18}\text{F}]\)fluoride/kryptofix complex. Subsequently, these synthons are reacted with the (functionalized) peptide, leading to longer synthesis times and lower overall yields.

More recently, a method based on Si-F has been published, in which the \(^{18}\text{F}\) is bound to a silicon-containing building block in a single step [13, 14]. Although somewhat similar to our approach, the Si-\(^{18}\text{F}\) initially proved to be unstable, but could be stabilized by the addition of tertiary butyl groups. This, however, leads to a strong increase in lipophilicity (log \(P\), 1.3±0.1).

Finally, “click” chemistry has been explored for the radiofluorination of peptides [9–11]. Although the yield of these click chemistry-based labeling procedures based on the alkyn-azole cycloaddition is excellent (>80%), the method starts with the fluorination of an azide or alkyne, such as fluoro(ethyl)azide or a fluoroalkyne. This requires azeotropic drying of the fluoride, resulting in a time-consuming multistep procedure. Recently, the radiosynthesis of a [\(^{18}\text{F}\)]fluoroethyl triazole-labeled [Tyr\(^3\)]octreotate has been described using a copper-catalyzed azide-alkyne cycloaddition reaction [8]. The [\(^{18}\text{F}\)]fluoroethyl azide was produced in 50% decay-corrected yields and the click reaction proceeded in 5 min at room temperature in 50–66% decay-corrected yields.

Compared to a \(^{68}\text{Ga}\) labeling, the Al\(^{18}\text{F}\) method is easy and versatile, mainly due to the fact that both methods are based on a chelator-derivatized peptide. One of the advantages of the Al\(^{18}\text{F}\) method is the longer half-life of \(^{18}\text{F}\), allowing PET scanning at later timepoints after injection of the tracer.

**Conclusion**

In conclusion, our new approach combines the ease of chelator-based radiolabeling methods with the advantages of \(^{18}\text{F}\) (i.e., half-life, availability, and positron energy). The Al\(^{18}\text{F}\)-labeled NOTA-octreotide could be synthesized carrier-free in quantitative yields in <45 min without the need to synthesize an \(^{18}\text{F}\) synthon. Moreover, the fluorinated peptide was stable in vitro and in vivo and has excellent tumor-targeting properties. Therefore, this fluorination method is a promising facile and versatile fluorination procedure.

**Acknowledgments** We thank Bianca Lemmers-de Weem and Kitty Lemmens-Hermans for technical assistance. This work was funded in part by NIH grant 5R44RR028018 from the National Center for Research Resources, Bethesda, MD, to WJM.

**Conflicts of interest** WJM, CAD’S, and DMG are employed or have financial interest in Immunomedics, Inc.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

**References**

1. Lang L, Eckelman WC. One-step synthesis of \(^{18}\text{F}\)-N-succinimidy-4-(fluoromethyl)benzoate for protein labeling. Appl Radiat Isot. 1994;45:1155–63.

2. Lang L, Eckelman WC. Labeling proteins at high specific activity using N-succinimidyl 4-[\(^{18}\text{F}\)]fluoromethyl) benzoate. Appl Radiat Isot. 1997;48:169–73.

3. Poethko T, Schottelius M, Thumshirn U, Hersel M, Henriksen G, et al. Two-step methodology for high-yield routine radiohalogenation of peptides: \(^{18}\text{F}\)-labeled RGD and octreotide analogs. J Nucl Med. 2004;45:892–902.

4. Bruus-Jensen K, Poethko T, Schottelius M, Hauser A, Schwaiger M, Wester HJ. Chemoselective hydrazone formation between HYNIC-functionalized peptides and F-18-fluorinated aldehydes. Nucl Med Biol. 2006;33:73–83.

5. Rennen HJ, Laverman P, van Eerd JE, Oyen WJ, Corstens FH. Radiofluorination of peptides: \(^{18}\text{F}\)-labeled RGD and octreotide analogs. J Nucl Med. 2007;34:691–5.

6. Hultsch C, Schottelius M, Auerhammer J, Alke A, Wester HJ. \(^{18}\text{F}\)-Fluoroglucosylation of peptides, exemplified on cyclo (RGDJK). Eur J Nucl Med Mol Imaging. 2009;36:1469–74.

7. Namavari M, Cheng Z, Zhang R, De A, Levi J, Hoerner JK, et al. A novel method for direct site-specific radio labeling of peptides using \([^{18}\text{F}]\)FDG. Bioconjug Chem. 2009;20:432–6.

8. Iddon L, Leyton J, Indrevoll B, Glaser M, Robins EG, George AJT, et al. Synthesis and in vitro evaluation of \([^{18}\text{F}]\)fluoroethyl triazole labelled [Tyr\(^3\)]octreotate analogues using click chemistry. Bioorg Med Chem Lett. 2011;21:3122–7.

9. Glaser M, Arstad E. "Click labeling" with 2-[\(^{18}\text{F}\)]fluoroethylazide for positron emission tomography. Bioconjug Chem. 2007;18:989–93.

10. Hausner SH, Marik J, Gagnon MK, Sutcliffe JL. In vivo positron emission tomography (PET) imaging with an \(\alpha/\beta\) specific peptide radiolabeled using \(^{18}\text{F}\)-"click" chemistry: evaluation and comparison with the corresponding 4-[\(^{18}\text{F}\)]fluorobenzoyl- and 2-[\(^{18}\text{F}\)]fluoropropionyl-peptides. J Med Chem. 2008;51:5901–4.

11. Marik J, Sutcliffe JL. Click for PET: rapid preparation of \([^{18}\text{F}]\)fluoropeptides using Cu-I catalyzed 1,3-dipolar cycloaddition. Tetrahedron Lett. 2006;47:6681–4.

12. Li ZB, Wu Z, Chen K, Chin FT, Chen X. Click chemistry for \(^{18}\text{F}\)-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug Chem. 2007;18:1987–94.

13. Hohne A, Mu L, Honer M, Schubiger PA, Ametamey SM, Graham K, et al. Synthesis, \(^{18}\text{F}\)-labeling, and in vitro and in vivo studies of bombesin peptides modified with silicon-based building blocks. Bioconjug Chem. 2008;19:1871–9.

14. Mu L, Hohne A, Schubiger PA, Ametamey SM, Graham K, Cyr JE, et al. Silicon-based building blocks for one-step \(^{18}\text{F}\)-radio-labeling of peptides for PET imaging. Angew Chem Int Ed Engl. 2008;47:4922–5.

15. McBride WJ, D’Souza CA, Sharkey RM, Karacay H, Rossi EA, Chang CH, et al. Improved \(^{18}\text{F}\) labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem. 2010;21:1331–40.
16. Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJG, et al. A novel facile method of labeling octreotide with (18) F-fluorine. J Nucl Med. 2010;51:454–61.
17. McBride WJ, Sharkey RM, Karacay H, D’Souza CA, Rossi EA, Laverman P, et al. A novel method of 18F radiolabeling for PET. J Nucl Med. 2009;50:991–8.
18. Visser EP, Disselhorst JA, Brom M, Laverman P, Gotthardt M, Oyen WJ, et al. Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med. 2009;50:139–47.
19. D’Souza C, McBride WJ, Sharkey RM, Todara LJ, Goldenberg DM. High-yielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem. 2011;22:1793–803.
20. Rajan KS, Mainer S, Rajan NL, Davis JM. Studies on the chelation of aluminum for neurobiological application. J Inorg Biochem. 1981;14:339–50.
21. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging. 2000;27:273–82.
22. Guhlke S, Wester HJ, Bruns C, Stocklin G. (2-[18F]fluoropropionyl-(D)phe’)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. Nucl Med Biol. 1994;21:819–25.